Medicare drug rebates: lower bills for cancer patients, but complex rules ahead
H.R. 4299 — Protecting Patient Access to Cancer and Complex Therapies Act · Filed by Gregory Murphy (R-NC) · 42 cosponsors · Introduced Jul 7, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill modifies how Medicare pays for cancer and complex therapies by creating a rebate mechanism tied to maximum fair price (MFP) negotiations. When a drug's negotiated price falls below the current ASP+6 payment formula, manufacturers must rebate the difference to Medicare quarterly; patients' coinsurance is recalculated based on the lower negotiated price rather than the higher ASP+6 amount. The bill essentially locks in savings from price negotiations at both the program and patient level.
Why we flagged it
The bill's core function is to operationalize rebates from manufacturers when negotiated drug prices fall below the current ASP+6 payment standard, creating a financial pass-through to Medicare and patients. It is a technical amendment to existing price-negotiation authority, not a new policy.
What the text implies
- The rebate mechanism may incentivize manufacturers to avoid negotiating lower prices if rebate obligations are perceived as punitive, potentially undermining the intent of price negotiation.
- Quarterly rebate calculations and reporting requirements create significant administrative overhead for manufacturers and CMS, which could delay rebate processing and patient benefit realization.
The full analysis lists 4 implications of this text.
Who stands to gain
Medicare program (rebate deposits); Medicare beneficiaries (lower coinsurance); Potentially: generic/biosimilar manufacturers if negotiated prices favor lower-cost alternatives